Ranibizumab (Lucentis®) is a non-glycosylated monoclonal antibody fragment (Fab) created from the humanized Bevazizumab (Avastin®) antibody but expressed in e.coli. There are slight differences in the amino acid sequence in the VEGF-binding region. VEGF-A Protein is considered an activator of blood vessel growth which can lead to vision loss in the eye, especially in the disease that is called wet type of age related macular degeneration (AMD).

The solution is directly injected into the eye so that the fragment binds to the VEGF-A protein to inhibit angiogenesis and therefore hinder further vision loss.

The patent expiry is in 2017. PPS has experience in the analysis of different variants of Ranibizumab originators and biosimilars.

To support the analytical development of Ranibizumab biosimilars or biobetters, PPS has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification

The specific bioassays are performed by a strategic partner:

  • Target: VEGF Assay type: Neutralization/proliferation Assay


Your contact for Ranibizumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com